NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: BPLPHARMA · data 2026-11-01
Bharat Parenterals Ltd.
In plain words
Price: 11.6% below its 52-week high of ₹2,295.1.
Delivery: 43.3% of traded shares were kept for delivery over the last 10 sessions, against 61.5% over the last 52.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹395 cr |
| Net profit (last 12 months) | ₹1 cr |
| Sales growth, 3 years (yearly) | 16.5% |
| Profit growth, 3 years (yearly) | — |
At a glance
P/E 1124.7, P/B 4.2, dividend yield 0.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE -2.5%, ROCE -4.2%, operating margin -0.4%: how much profit it earns on the money it uses.
Debt/equity 0.45, Profit growth — and sales growth 16.5% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (-2.5%).
- Thin operating margin (-0.4%).
- Expensive on earnings (P/E 1124.7).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
11/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 6/30: Delivery 37.2% over the last 20 sessions vs 45.6% in the 40 before (0.82x); shares delivered per day 1.23x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend
- 11 Sept 26Dividend Dividend ₹1 (ex-date) -1.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Common questions
Is Bharat Parenterals Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.45.
What is Bharat Parenterals Ltd.'s P/E ratio?
About 1,124.7, based on the last 12 months' earnings and a price of ₹2,029.9 (data 2026-11-01).
What is the 52-week high and low of Bharat Parenterals Ltd.?
The 52-week high is ₹2,295.1 and the 52-week low is ₹1,125.7.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Bharat Parenterals Ltd. | ₹2,029.9 | ₹1,397 cr | 1,124.7 | 4.2 | -2.5% | -4.2% | 0.45 | +45.0% |
| Venus Remedies Limited | ₹1,238.6 | ₹1,646 cr | 13.6 | 2.4 | 16.8% | 14.5% | 0.02 | +182.9% |
| NGL Fine-Chem Ltd. | ₹2,526 | ₹1,576 cr | 27.3 | — | 15.7% | 17.1% | 0.37 | +66.0% |
| Accent Microcell Limited | ₹639 | ₹1,533 cr | 26.9 | 5 | 18.7% | 22.7% | 0 | +140.2% |
| Anlon Healthcare Limited | ₹25.89 | ₹1,378 cr | 38.6 | 5.4 | 18.4% | 24.3% | 0.19 | +108.0% |
| TTK Healthcare Limited | ₹905.3 | ₹1,280 cr | 17.3 | — | 6% | 2.1% | 0.02 | -23.2% |
Compare BPLPHARMA with VENUSREM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open BPLPHARMA in NSE Scanner →